A Phase 1, Randomised, Single-blind, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Elarekibep Given Twice Daily as Inhaled or a Single IV Formulation in Healthy Japanese Subjects
Latest Information Update: 19 Jul 2023
At a glance
- Drugs Elarekibep (Primary) ; Elarekibep (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 17 Jul 2023 Status changed to discontinued.
- 12 Jul 2023 Status changed from recruiting to completed.
- 25 May 2023 Planned number of patients changed from 42 to 40.